Alpha-actinin-4 as an oncogenic driver and therapeutic target in melanoma

Alpha-actinin-4 作为黑色素瘤的致癌驱动因素和治疗靶点

• 批准号: nhmrc : 1099947
• 负责人: Dr Lei Jin
• 金额: $ 27.55万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/alpha-actinin-4-target-melanoma/662482
• 关键词: Alpha; actinin; oncogenic; driver; therapeutic

Despite the recent advances in targeted therapy and immunotherapy, curative treatment of metastatic melanoma remains an unmet health problem. In this project, we will potentially demonstrate that a protein called ACTN4 is abnormally expressed at high levels in melanoma cells and plays an important role for melanoma cell survival and resistance to treatment, and thus identify inhibition of ACTN4, either alone or in combination with other drugs, as a novel approach in the treatment of melanoma.

尽管最近在靶向治疗和免疫治疗方面取得了进展，但转移性黑色素瘤的治愈性治疗仍然是一个未解决的健康问题。在本项目中，我们将潜在地证明一种名为ACTN 4的蛋白质在黑色素瘤细胞中异常高水平表达，并对黑色素瘤细胞的生存和治疗抵抗力发挥重要作用，从而确定单独或与其他药物联合抑制ACTN 4，作为治疗黑色素瘤的新方法。